<DOC>
	<DOCNO>NCT00895232</DOCNO>
	<brief_summary>Non-randomized open label Phase II clinical trial subject meet criterion RLS assign 1 3 treatment cohort . The first cohort receive one 500 mg IV iron sucrose infusion 500 mL normal sterile saline ( NSS ) administer four hour . The second cohort receive two 500 mg IV iron sucrose infusion 500mL NSS administer four six hour two separate date , separate two seven day . The third cohort receive two 500 mg IV iron sucrose infusion least 500 mL NSS six hour within 30 hour start first infusion . Cohorts enrol treat subsequently .</brief_summary>
	<brief_title>Iron Sucrose In The Treatment Restless Legs Syndrome : Safety Three Dose Regimens Evaluated Clinical Assessments</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Signed consent . Male female subject &gt; 18 yr . old . RLS sign symptom affirm diagnosis . A baseline score &gt; = 15 required International RLS Study Group Rating Scale ( IRLSSG ) . At least one leg average baseline Periodic Leg Movement ( PLM ) asleep &gt; = 15 movement per hour actigraphy . Subjects dopaadrenergic therapy RLS treatment must therapy least one week baseline RLS assessment actigraphy measurement obtain . Subject regular sleep hour 9 p.m. 9 a.m . Subjects risk pregnancy must negative pregnancy test baseline practice acceptable form birth control . Known intolerance Venofer . RLS ascribe renal disease . RLS 2Â° CNS disease injury . Any pain related sleep relate disorder may confound outcome measure . History neuroleptic akinesia . Concurrent use oral iron supplement . Parenteral iron use within past 6 month . Active infection . Currently treat asthma . Severe peripheral vascular disease significant skin change . Seizure disorder currently treat medication . Serum ferritin level &gt; 300 ng/mL TSAT &gt; = 45 % baseline history hemochromatosis . Significant cardiovascular hepatic disease preexist medical condition disease view investigator participation study would put subject 's disease management risk subject would unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>